The Impact of FGFR4 Gene SNP (Rs 1966265) on the Progression of Colorectal Cancer in Some Iraqi Patients

Authors

  • Hayder Mazin Alhaboobi University of Baghdad, Institute of Genetic Engineering and Biotechnology for Post Graduate
  • Hamsa Ahmed Jasim University of Baghdad, Institute of Genetic Engineering and Biotechnology for Post Graduate
  • Susan Zwya College of Health and Medical Technology, Middle Technical University

Keywords:

colorectal cancer, single-nucleotide polymorphism

Abstract

The high death and prevalence risk of colorectal cancer (CRC) continue to be a worldwide health consequence due to its complex nature. The protein receptor fibroblast expansion element 4 with the aberrant regulatory sequences it activates have been found to have a significant impact on cancer formation and survival. The purpose of this research was to examine the role of FGFR4 genetic polymorphisms in CRC formation and progression. Fifty colorectal cancer cases and fifty non-cancerous controls were analyzed for the FGFR4 SNP. Neither the case nor the control groups showed any discernible SNP-related increase in Cancer risk. Participants with rectal cancer who have at minimum one small mutation of rs1966265 (AG and GG; AOR, 0.256; p = 0.36) become more likely to acquire metastases likened to those with heterozygous for the main allele.

References

Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]

Kuo, C.N.; Liao, Y.M.; Kuo, L.N.; Tsai, H.J.; Chang, W.C.; Yen, Y. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. J. Formos. Med. Assoc. 2020, 119, 1731–1741. [CrossRef] [PubMed]

Su, S.Y.; Huang, J.Y.; Jian, Z.H.; Ho, C.C.; Lung, C.C.; Liaw, Y.P. Mortality of colorectal cancer in Taiwan, 1971-2010: Temporal changes and age-period-cohort analysis. Int. J. Colorectal Dis. 2012, 27, 1665–1672. [CrossRef] [PubMed]

Hull, R.; Francies, F.Z.; Oyomno, M.; Dlamini, Z. Colorectal Cancer Genetics, Incidence and Risk Factors: In Search for Targeted Therapies. Cancer Manag. Res. 2020, 12, 9869–9882. [CrossRef] [PubMed]

Takayama, T.; Miyanishi, K.; Hayashi, T.; Sato, Y.; Niitsu, Y. Colorectal cancer: Genetics of development and metastasis. J. Gastroenterol. 2006, 41, 185–192. [CrossRef] [PubMed]

Brennan, C.A.; Garrett, W.S. Gut Microbiota, Inflammation, and Colorectal Cancer. Annu. Rev. Microbiol. 2016, 70, 395–411. [CrossRef]

Babina, I.S.; Turner, N.C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 2017, 17, 318–332. [CrossRef]

Liu, Y.; Cao, M.; Cai, Y.; Li, X.; Zhao, C.; Cui, R. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression. Front. Cell Dev. Biol. 2020, 8, 95. [CrossRef]

Pai, R.; Dunlap, D.; Qing, J.; Mohtashemi, I.; Hotzel, K.; French, D.M. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res. 2008, 68, 5086–5095. [CrossRef]

Hart, K.C.; Robertson, S.C.; Kanemitsu, M.Y.; Meyer, A.N.; Tynan, J.A.; Donoghue, D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19, 3309–3320. [CrossRef]

Touat, M.; Ileana, E.; Postel-Vinay, S.; Andre, F.; Soria, J.C. Targeting FGFR Signaling in Cancer. Clin. Cancer Res. 2015, 21, 2684–2694. [CrossRef]

Farnebo, L.; Tiefenbock, K.; Ansell, A.; Thunell, L.K.; Garvin, S.; Roberg, K. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int. J. Cancer 2013, 133, 1994–2003. [CrossRef] [PubMed]

Chou, C.H.; Hsieh, M.J.; Chuang, C.Y.; Lin, J.T.; Yeh, C.M.; Tseng, P.Y.; Yang, S.F.; Chen, M.K.; Lin, C.W. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. Oncotarget 2017, 8, 96225–96238. [CrossRef] [PubMed]

Li, J.P.; Huang, H.C.; Yang, P.J.; Chang, C.Y.; Chao, Y.H.; Tsao, T.C.; Huang, H.; Hung, Y.C.; Hsieh, M.J.; Yang, S.F. FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan. Int. J. Environ. Res. Public Health 2020, 17, 5694. [CrossRef] [PubMed]

Ma, Z.; Tsuchiya, N.; Yuasa, T.; Inoue, T.; Kumazawa, T.; Narita, S.; Horikawa, Y.; Tsuruta, H.; Obara, T.; Saito, M.; et al.

Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int. J. Cancer 2008, 123, 2574–2579.

Wang, J.; Stockton, D.W.; Ittmann, M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin. Cancer Res. 2004, 10, 6169–6178. [CrossRef]

Marme, F.; Werft, W.; Benner, A.; Burwinkel, B.; Sinn, P.; Sohn, C.; Lichter, P.; Hahn, M.; Schneeweiss, A. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann. Oncol. 2010, 21, 1636–1642. [CrossRef]

Bange, J.; Prechtl, D.; Cheburkin, Y.; Specht, K.; Harbeck, N.; Schmitt, M.; Knyazeva, T.; Muller, S.; Gartner, S.; Sures, I.; et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002, 62, 840–847.

Marme, F.; Hielscher, T.; Hug, S.; Bondong, S.; Zeillinger, R.; Castillo-Tong, D.C.; Sehouli, J.; Braicu, I.; Vergote, I.; Isabella, C.; et al. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int. J. Cancer 2012, 131, E586–E591. [CrossRef]

Yang, Y.; Zhou, Y.; Lu, M.; An, Y.; Li, R.; Chen, Y.; Lu, D.R.; Jin, L.; Zhou, W.P.; Qian, J.; et al. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol. Carcinog. 2012, 51, 515–521. [CrossRef]

Chen, T.H.; Yang, S.F.; Liu, Y.F.; Lin, W.L.; Han, C.P.; Wang, P.H. Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis. Reprod. Sci. 2018, 25, 86–93. [CrossRef]

Edge, S.B.; Compton, C.C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 2010, 17, 1471–1474. [CrossRef] [PubMed]

Tsay, M.D.; Hsieh, M.J.; Lee, C.Y.;Wang, S.S.; Chen, C.S.; Hung, S.C.; Lin, C.Y.; Yang, S.F. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma. Int. J. Environ. Res. Public Health 2019, 17, 129. [CrossRef]

Wong, B.S.; Camilleri, M.; Carlson, P.J.; Guicciardi, M.E.; Burton, D.; McKinzie, S.; Rao, A.S.; Zinsmeister, A.R.; Gores, G.J. A Klothobeta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011, 140, 1934–1942. [CrossRef] [PubMed]

Ajouz, H.; Mukherji, D.; Shamseddine, A. Secondary bile acids: An underrecognized cause of colon cancer. World J. Surg. Oncol. 2014, 12, 164. [CrossRef] [PubMed]

Liu, T.; Song, X.; Khan, S.; Li, Y.; Guo, Z.; Li, C.; Wang, S.; Dong, W.; Liu, W.; Wang, B.; et al. The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing. Int. J. Cancer 2020, 146, 1780–1790. [CrossRef]

Jiang, Y.; Sun, S.;Wei, W.; Ren, Y.; Liu, J.; Pang, D. Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province. Oncotarget 2015, 6, 34023–34029. [CrossRef]

Downloads

Published

2024-06-22

How to Cite

Alhaboobi, H. M., Jasim, H. A., & Zwya, S. (2024). The Impact of FGFR4 Gene SNP (Rs 1966265) on the Progression of Colorectal Cancer in Some Iraqi Patients. American Journal of Social and Humanitarian Research, 5(6), 37–41. Retrieved from https://globalresearchnetwork.us/index.php/ajshr/article/view/2807

Issue

Section

Articles